This Phase II study is being conducted at multiple centres to evaluate the effectiveness of a drug called Roginolisib in treating advanced or metastatic ocular/uveal melanoma. The study is open-label, meaning all participants will know they are receiving the treatment, and participants will be randomly assigned to different treatment groups to assess the anti-tumour activity […]
Study of Roginolisib in UM Patients (OCULE-01) Read More »
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Participants must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme.
Researchers are exploring better ways to manage people with intermediate or high-risk resected cutaneous melanoma or primary uveal melanoma. This study is investigating the use of a new blood test to guide when to administer a drug called tebentafusp. Tebentafusp has previously been tested in clinical trials for patients with advanced cutaneous and uveal melanoma.
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD) Read More »
